| Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors PT Männistö, S Kaakkola Pharmacological reviews 51 (4), 593-628, 1999 | 1378 | 1999 |
| Neurotransmitter regulation of anterior pituitary hormones J Tuomisto, P Männistö Pharmacological Reviews 37 (3), 249-332, 1985 | 691 | 1985 |
| Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis P Seeman, D Weinshenker, R Quirion, LK Srivastava, SK Bhardwaj, ... Proceedings of the National Academy of Sciences 102 (9), 3513-3518, 2005 | 438 | 2005 |
| Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cγ signaling pathways in mouse brain T Rantamäki, P Hendolin, A Kankaanpää, J Mijatovic, P Piepponen, ... Neuropsychopharmacology 32 (10), 2152-2162, 2007 | 357 | 2007 |
| Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum L Yavich, MM Forsberg, M Karayiorgou, JA Gogos, PT Männistö Journal of Neuroscience 27 (38), 10196-10209, 2007 | 334 | 2007 |
| On the role of prolyl oligopeptidase in health and disease JA García-Horsman, PT Männistö, JI Venäläinen Neuropeptides 41 (1), 1-24, 2007 | 292 | 2007 |
| Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors PT Männistö, I Ulmanen, K Lundström, J Taskinen, J Tenhunen, ... Progress in drug research. Fortschritte der Arzneimittelforschung. Progres …, 1992 | 269* | 1992 |
| Brain catecholamine metabolism in catechol‐O‐methyltransferase (COMT)‐deficient mice M Huotari, JA Gogos, M Karayiorgou, O Koponen, M Forsberg, ... European Journal of Neuroscience 15 (2), 246-256, 2002 | 239 | 2002 |
| Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice M Käenmäki, A Tammimäki, T Myöhänen, K Pakarinen, C Amberg, ... Journal of neurochemistry 114 (6), 1745-1755, 2010 | 221 | 2010 |
| Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis A Tammimäki, PT Männistö Pharmacogenetics and genomics 22 (9), 673-691, 2012 | 193 | 2012 |
| The multiple faces of quercetin in neuroprotection B Ossola, TM Kääriäinen, PT Männistö Expert opinion on drug safety 8 (4), 397-409, 2009 | 189 | 2009 |
| Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease PT Männistö, S Kaakkola Pharmacology & toxicology 66 (5), 317-323, 1990 | 176 | 1990 |
| Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease MH Voutilainen, S Bäck, J Peränen, P Lindholm, A Raasmaja, ... Experimental neurology 228 (1), 99-108, 2011 | 168 | 2011 |
| General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase S Kaakkola, A Gordin, PT Männistö General Pharmacology: The Vascular System 25 (5), 813-824, 1994 | 163 | 1994 |
| 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety V Volke, A Soosaar, S Ko˜ ks, M Bourin, PT Männistö, E Vasar Psychopharmacology 131, 399-405, 1997 | 162 | 1997 |
| New selective COMT inhibitors: useful adjuncts for Parkinson's disease? PT Männistö, S Kaakkola Trends in pharmacological sciences 10 (2), 54-56, 1989 | 146 | 1989 |
| Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. PT Maennisto, J Venäläinen, A Jalkanen, JA García-Horsman Drug news & perspectives 20 (5), 293-305, 2007 | 134 | 2007 |
| Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat E Nissinen, IB Lindén, E Schultz, S Kaakkola, PT Männistö, P Pohto European journal of pharmacology 153 (2-3), 263-269, 1988 | 134 | 1988 |
| Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task T Koskinen, S Ruotsalainen, T Puumala, R Lappalainen, E Koivisto, ... Neuropharmacology 39 (3), 471-481, 2000 | 128 | 2000 |
| A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease TT Myöhänen, MJ Hannula, R Van Elzen, M Gérard, P Van Der Veken, ... British journal of pharmacology 166 (3), 1097-1113, 2012 | 126 | 2012 |
